These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11966681)

  • 1. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
    Goldstein JA
    Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2C9 polymorphism and warfarin dose requirements.
    Daly AK; Day CP; Aithal GP
    Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 4. Warfarin dose requirement and CYP2C9 polymorphisms.
    Halkin H; Lubetsky A
    Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J
    Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
    Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
    Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
    Nasu K; Kubota T; Ishizaki T
    Pharmacogenetics; 1997 Oct; 7(5):405-9. PubMed ID: 9352578
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic and functional variability of cytochrome P4502C9.
    Bhasker CR; Miners JO; Coulter S; Birkett DJ
    Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
    Yasar U; Eliasson E; Dahl ML
    Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
    Aithal GP; Day CP; Leathart JB; Daly AK
    Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9*3 allelic variant and bleeding complications.
    Ogg MS; Brennan P; Meade T; Humphries SE
    Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
    [No Abstract]   [Full Text] [Related]  

  • 15. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 16. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
    Thijssen HH; Verkooijen IW; Frank HL
    Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
    [No Abstract]   [Full Text] [Related]  

  • 17. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.
    London SJ; Sullivan-Klose T; Daly AK; Idle JR
    Pharmacogenetics; 1997 Oct; 7(5):401-4. PubMed ID: 9352577
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
    Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
    Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the CYP2C9 gene and the response to warfarin.
    Yasar U; Oscarson M; Eliasson E; Sjöqvist F
    Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.